← Back to Clinical Trials
Recruiting NCT06116903

Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes

Trial Parameters

Condition Glioma
Sponsor University Hospital, Limoges
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-04-11
Completion 2025-05-15
Interventions
Blood sampling

Brief Summary

The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.

Eligibility Criteria

Inclusion Criteria: * Subject of both sexes at least 18 years of age with glioblastoma. * Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol) * Patient affiliated to French social security Exclusion Criteria: * Patient included in another research protocol using an experimental molecule. * Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol * Patient under legal protection, guardianship or curatorship * Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.

Related Trials